undamentalytics Newsletter
Sign in

Protagonist Therapeutics, Inc revenue

Protagonist Therapeutics, Inc's revenue was $46.0m in fiscal 2025, down 89.4% on the year before. Since fiscal 2017 ($20.1m) it has grown at a compound 10.9% a year. Over the last twelve months it was $282m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue203102927276043446282
Growth on the year before—+54.1%−99.3%+>999%−4.4%−2.8%+125.7%+624.1%−89.4%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Protagonist Therapeutics, Inc $282m 34.8% —
Phathom Pharmaceuticals, Inc. $275m 86.8% —
Syndax Pharmaceuticals Inc $290m 159.7% 177.8%
Vir Biotechnology, Inc. $303m 1495.9% -14.8%
Vericel Corp $306m 23.0% 19.8%
Adaptive Biotechnologies Corp $308m 50.1% 17.6%

Compare with peers

Head to head: PHAT vs PTGXPTGX vs SNDXPTGX vs VIR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Protagonist Therapeutics, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Protagonist Therapeutics, Inc.